Bolt Biotherapeutics, Inc. Common Stock

BOLTNASDAQ • USD
4.91 USD
↘ 0.15 (2.96%)AT CLOSE (03:59 PM EST)
4.97
↗ 0.06 (1.12%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
4.97
↗ 0.06 (1.12%)
🔴Market: CLOSED

Shares of Bolt Biotherapeutics, Inc. Common Stock (BOLT) are trading at $4.91. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 20, 2026.

Open?$5.05
High?$5.21
Low?$4.87
Prev. Close?$5.06
Volume?60.5K
Avg. Volume?515.6K
VWAP?$5.03
Rel. Volume?0.12x
Bid / Ask
Bid?$3.89 × 100
Ask?$5.50 × 100
Spread?$1.61
Midpoint?$4.70
Valuation & Ratios
Market Cap?13.2M
Shares Out?1.9M
Float?1.4M
Float %?74.6%
P/E Ratio?N/A
P/B Ratio?1.04
EPS?-$11.02
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Employees
23
Market Cap
13.2M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-02-05
Address
900 CHESAPEAKE DRIVE
REDWOOD CITY, CA 94063
Phone: 650-665-9295
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
23
Short Sent.?
71
Piotroski F-Score?1/9Weak
Altman Z-Score?-18.25Distress
Confidence?50%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?3.30%Low
Short Interest?47.4K
Days to Cover?1.0
Free Float1.4M
Avg Daily Volume1.3M
Settlement Date2026-10-30
Financial Health
Current Ratio?2.61Strong
Quick Ratio?2.61Strong
Cash Ratio?1.63Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
1.04CHEAP▾
P/S?
Peers
100
S&P
53
2.81CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.0CHEAP▾
EV/Sales?
Peers
100
S&P
97
0.07CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-227.4%WEAK▾
ROA?
S&P
3
-71.2%WEAK▾
Cash Flow & Enterprise
FCF?$-31536000
Enterprise Value?$333.9K
Fundamentals ratios updated end of day